Myeloperoxidase Gene Deletion Causes Drastic Microbiome Shifts in Mice and Does Not Mitigate Dextran Sodium Sulphate-Induced Colitis

Patrick T. San Gabriel,Thomas R. O’Neil,Alice Au,Jian K. Tan,Gabriela V. Pinget,Yuyang Liu,Genevieve Fong,Jacqueline Ku,Elias Glaros,Laurence Macia,Paul K. Witting,Shane R. Thomas,Belal Chami,Thomas R. O'Neil
DOI: https://doi.org/10.3390/ijms25084258
IF: 5.6
2024-04-12
International Journal of Molecular Sciences
Abstract:Neutrophil-myeloperoxidase (MPO) is a heme-containing peroxidase which produces excess amounts of hypochlorous acid during inflammation. While pharmacological MPO inhibition mitigates all indices of experimental colitis, no studies have corroborated the role of MPO using knockout (KO) models. Therefore, we investigated MPO deficient mice in a murine model of colitis. Wild type (Wt) and MPO-deficient mice were treated with dextran sodium sulphate (DSS) in a chronic model of experimental colitis with three acute cycles of DSS-induced colitis over 63 days, emulating IBD relapse and remission cycles. Mice were immunologically profiled at the gut muscoa and the faecal microbiome was assessed via 16S rRNA amplicon sequencing. Contrary to previous pharmacological antagonist studies targeting MPO, MPO-deficient mice showed no protection from experimental colitis during cyclical DSS-challenge. We are the first to report drastic faecal microbiota shifts in MPO-deficient mice, showing a significantly different microbiome profile on Day 1 of treatment, with a similar shift and distinction on Day 29 (half-way point), via qualitative and quantitative descriptions of phylogenetic distances. Herein, we provide the first evidence of substantial microbiome shifts in MPO-deficiency, which may influence disease progression. Our findings have significant implications for the utility of MPO-KO mice in investigating disease models.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the impact of myeloperoxidase (MPO) gene knockout on the mouse colitis model. Specifically, by constructing a mouse model with MPO gene knockout, the researchers aim to investigate the role of MPO in experimental colitis and whether this gene knockout can alleviate the symptoms of colitis induced by dextran sodium sulphate (DSS). In addition, the study also focuses on the impact of MPO gene knockout on the gut microbial community in mice to understand how MPO deficiency affects the gut microbial composition and its relationship with the development of colitis. The research background indicates that although pharmacological inhibition of MPO can relieve all indicators of experimental colitis, no study has yet used a gene knockout model to verify the role of MPO. Therefore, this study fills this gap, provides new insights into the role of MPO in colitis, and reveals that significant changes occur in the gut microbiome of MPO - knockout mice, and these changes may have an impact on the disease process.